ClearB Therapeutics Licenses Novel Saponin Adjuvant TQL-1055, to Present Hepatitis B Vaccine Data at AASLD 2024
ClearB Therapeutics, a company focused on developing therapeutic vaccines for a functional cure of Hepatitis B, has licensed the novel saponin-based adjuvant TQL-1055 from Adjuvance Technologies. The adjuvant will be used in combination with ClearB’s proprietary Hepatitis B surface antigen (HBsAg) variants, CLB-405 and CLB-505. Preclinical data on this therapeutic vaccine approach will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024, taking place in San Diego, CA, from November 15-19.
“We’re excited to share preclinical results on our next-generation vaccine candidate with the Hepatitis B community,” said Aileen Rubio, PhD, CEO of ClearB Therapeutics. “Chronic Hepatitis B remains a major global health challenge in need of effective therapies. The unique adjuvant properties of TQL-1055 could enhance the functional cure potential of our HBsAg variants, making them a valuable component of combination treatments.”
Tyler Martin, MD, Director and CEO of Adjuvance Technologies, added, “ClearB is developing a game-changing vaccine for patients with chronic Hepatitis B, and we are pleased that TQL-1055 will be part of this effort. We look forward to supporting their work to transform the lives of millions affected by the disease.”
- Upcoming Poster Presentations at AASLD 2024:
- Abstract #1308: “Tolerability and immunogenicity of HBsAg variants, CLB-405 and CLB-505, combined with a novel semi-synthetic saponin adjuvant TQL-1055, in New Zealand white rabbits.”
Date: November 15, 2024 | Presenter: Dr. Aditi Deshpande, ClearB Therapeutics - Abstract #1305: “CLB-405 and CLB-505 combined with saponin-based adjuvant TQL-1055 exhibit strong antiviral and enhanced immune responses in a mouse model of persistent Hepatitis B infection.”
Date: November 15, 2024 | Presenter: Dr. Aditi Deshpande, ClearB Therapeutics - Abstract #1307: “Sequential administration of siRNA with CLB-405 and CLB-505 HBsAg variants encoding clearance profile epitopes, combined with novel adjuvant TQL-1055, shows significant antiviral and T cell activity in an AAV/HBV mouse model.”
Date: November 15, 2024 | Presenter: Dr. Aditi Deshpande, ClearB Therapeutics
These presentations will highlight the potential of the vaccine candidates to deliver antiviral effects and stimulate immune responses, marking a step toward advancing new therapeutic options for chronic Hepatitis B.
About ClearB Therapeutics
ClearB Therapeutics was founded in 2017 with technology licensed from the laboratory of Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is developing therapeutic vaccines designed to promote functional cure of Hepatitis B. The work is grounded in proprietary insights derived from studying rare-event resolution in patients who suffer from chronic Hepatitis B infection. For more information, please visit https://clearbtherapeutics.com/.
About TQL-1055
TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically-advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS-21 and has shown favorable tolerability in a Phase 1 clinical trial.
